The zoonotic pathogen Wohlfahrtiimonas chitiniclastica - current findings from a clinical and genomic perspective

Anna Kopf1,2, Boyke Bunk3, Thomas Riedel3,4

  • 1Clinic for Cardiology, Sana Heart Center, Leipziger Str. 50, 03048, Cottbus, Germany.

BMC Microbiology
|January 3, 2024
PubMed

Insights

Wohlfahrtiimonas chitiniclastica is a zoonotic bacterium causing human diseases like sepsis. This review examines its clinical and genomic aspects, highlighting antibiotic resistance concerns.

Area of Science:

  • Medical Microbiology
  • Zoonotic Diseases
  • Genomics

Background:

  • Wohlfahrtiimonas chitiniclastica is a zoonotic pathogen capable of causing severe human infections, including sepsis and bacteremia.
  • Infection typically occurs through traumatic skin lesions, often facilitated by fly larvae, leading to myiasis and wound contamination.
  • Risk factors include open wounds, poor sanitation, cardiovascular disease, substance abuse, and osteomyelitis.

Purpose of the Study:

  • To review and synthesize current knowledge on Wohlfahrtiimonas chitiniclastica.
  • To evaluate the pathogen from clinical and genomic perspectives.
  • To assess the implications of observed antibiotic resistance patterns.

Main Methods:

  • Literature review of clinical case studies and genomic analyses.
  • Synthesis of data on pathogenesis, transmission, and clinical manifestations.
  • Analysis of antibiotic susceptibility profiles and emerging resistance.

Main Results:

  • W. chitiniclastica infections are linked to specific environmental and host factors.
  • The bacterium is generally susceptible to most antibiotics, with notable resistance to fosfomycin.
  • Increasing trends in antibiotic resistance require careful monitoring.

Conclusions:

  • A comprehensive understanding of W. chitiniclastica pathogenesis and genomics is crucial for effective management.
  • Clinical vigilance and genomic surveillance are necessary to track and combat antibiotic resistance.
  • Further research is warranted to fully elucidate infection mechanisms and develop targeted therapies.

Related Concept Videos